Clinical Trials Using Methotrexate
Clinical trials are research studies that involve people. The clinical trials on this list are studying Methotrexate. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Cyclophosphamide and Abatacept for the Treatment of Graft-Versus-Host Disease after Stem Cell Transplantation in Patients with Hematologic Cancers
This phase II trial studies how well cyclophosphamide and abatacept work in reducing the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following donor stem cell transplantation in patients with hematologic (blood) cancers. GVHD occurs when the cells from the donor (the graft) see the body's cells (the host) as different and attack them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunosuppressive therapy, such as abatacept, is used to decrease the body’s immune response. The combination of cyclophosphamide and abatacept following donor stem cell transplantation may work better in reducing the incidence of moderate and severe chronic GVHD compared to standard of care.
Location: University of California San Diego, San Diego, California
Tacrolimus and Methotrexate with or without Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host-Disease in Patients with Hematological Malignancy Undergoing Donor Stem Cell Transplant
This phase III randomized clinical trial studies tacrolimus and methotrexate with or without mycophenolate mofetil in preventing graft-vs-host disease (GVHD) in patients with hematological malignancy undergoing donor stem cell transplant. Tacrolimus, methotrexate, and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by stem cell transplant. It is not yet known whether tacrolimus and methotrexate is more effective with or without mycophenolate mofetil in preventing GVHD.
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
Location: 5 locations
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
This phase II trial studies how well itacitinib works in preventing graft versus host disease in patients with blood disorders undergoing donor stem cell transplantation. A donor transplantation uses blood-making cells from a family member or unrelated donor to remove and replace abnormal blood cells. Graft versus host disease is a reaction of the donor's immune cells against the patient’s body. Itacitinib plus standard treatment may help prevent graft versus host disease in patients who have received a donor stem cell transplantation.
Location: M D Anderson Cancer Center, Houston, Texas
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
This pilot trial studies the side effects and feasibility of microdevice for in situ candidate drug screening in skin lesions of T-cell lymphoma. Implanting and retrieving a microdevice that releases up to 19 drugs directly within a skin lesion may be a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma or peripheral T cell lymphoma.
Location: 2 locations